Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and Cellular Senescence Pathways: Full Evidence Review

Previous related pageVitamin D and Cellular Senescence Pathways: Study SummaryNext related pageVitamin D and Cellular Senescence Pathways: Study Summary
Study at a glance

What question did the studies ask?

Researchers asked how vitamin D affects cells with features of senescence. Senescence is a state in which cells stop dividing for a long time but remain active. This review compares laboratory experiments and one small randomized human trial.

What did the researchers find?

Most laboratory studies used calcitriol, the active vitamin D hormone. Some experiments found changes in proteins involved in DNA repair. DNA is the material that carries genetic information. Others found lower release of selected inflammatory substances. Another improved a response to introduced DNA. These changes did not establish that the cells began dividing again or were removed. Other experiments found more senescence-associated features in injured human lung-cancer cells and kidney-cancer cells. Those models differ from healthy human tissue.

The human trial studied 88 older adults with low vitamin D levels. It compared two daily vitamin D3 doses, with or without N-acetylcysteine, for eight weeks. Higher-dose groups had lower selected blood-cell measurements than the lower dose alone. Some other measurements did not show a clear difference between groups. Blood inflammation measures did not show clear differences between groups. A staining result was not a direct count of senescent cells.

What does this mean?

Vitamin D can affect particular cell processes without establishing reversal of senescence. Laboratory hormone treatment, receptor deletion and oral vitamin D3 are different interventions. These studies did not establish that vitamin D clears senescent cells or slows ageing in people.

Read the full article below ↓

Vitamin D-related signalling changes several pathways associated with cellular senescence, but the experiments do not support a single universal anti-ageing effect. Depending on the model, calcitriol alters DNA-repair proteins, inflammatory secretions, growth-associated markers or responses to DNA challenge; some injured and malignant cells instead show more senescence-associated features. This review distinguishes those effects from reversal of stable growth arrest or removal of senescent cells. For a shorter account, read Vitamin D and Cellular Senescence Pathways: Study Summary.

What senescence measurements mean

Senescence describes a cell state involving durable withdrawal from division, together with other changes that vary by cell type and trigger. Repeated divisions, oncogene activation, irradiation and chemical injury create different experimental settings. A positive stain or altered gene is not a complete diagnosis on its own. The broader physiology is explained in Vitamin D and Cellular Senescence.

Three intervention claims must be kept separate. Preventing cells from entering senescence requires an appropriate comparison across that transition. Reversal of growth arrest requires evidence that previously arrested cells resume sustained division. A broader claim of senescence reversal also requires appropriate checks of the cell state. Better DNA repair, secretion or challenge responses alone do not establish either claim. Clearing senescent cells requires showing their selective removal. A fourth possibility is changing what surviving cells secrete. That may matter biologically without demonstrating any of the first three claims. A lower inflammatory signal cannot stand in for all of them. [1] [2] [3] [5]

This focused evidence review compares primary experiments rather than pooling unlike endpoints. Cultures, repeated measurements and animal arms within a paper are not independent studies. Most laboratory interventions used calcitriol, the active vitamin D hormone, whereas the small randomized human trial used oral cholecalciferol, or vitamin D3. Neither exposure is equivalent to deleting the vitamin D receptor, abbreviated VDR. Receptor biology is introduced in Vitamin D Receptors. The research doses below describe experiments and do not provide personal treatment advice.

Replicative ageing in human stromal cultures

Klotz and colleagues followed human marrow-derived mesenchymal stromal cells through serial passages, repeatedly transferring cells into fresh culture vessels. The overall programme involved 11 femoral-head donors, but individual assays used smaller subsets. Calcitriol at 100 nanomoles per litre slowed proliferation and changed selected morphology and senescence-associated measurements. The cells also retained the ability to undergo induced cartilage, fat and bone differentiation. This separates retained developmental potential from spontaneous commitment, a distinction developed in Vitamin D and Cell Differentiation. [1]

The title describes delayed cellular ageing, but the most defensible interpretation remains narrower than rejuvenation. Pooled cumulative population doublings did not significantly differ between treatment groups. Comparisons at the same passage can involve different elapsed times and division histories when treatment itself slows growth. Donor attrition and small assay-specific samples add uncertainty. Thus, changed late-passage markers do not establish an extended replicative lifespan or restored tissue function. [1]

The experiment also challenges a simple antioxidant explanation: reactive oxygen species increased at an early passage rather than falling uniformly. Reactive oxygen species are chemically reactive molecules that can contribute to both signalling and injury. The broader balance is discussed in Vitamin D and Oxidative Stress. The result does not identify one universal oxidative mechanism for vitamin D effects on senescence. [1]

Oncogene-induced arrest: DNA-repair proteins can improve without reversal

Graziano and colleagues activated an oncogenic form of Ras in fibroblast models, including telomerase-expressing cells. They measured VDR, BRCA1 and 53BP1, proteins involved in the response to DNA damage, and used gene silencing and repair-related assays. Ras activation lowered parts of this repair programme. Calcitriol at 100 nanomoles per litre restored selected repair-factor abundance or recruitment, but did not prevent the oncogene-induced senescent arrest. [2]

That negative result determines the interpretation. Repair-factor recovery and release from growth arrest are different outcomes. A DNA-damage focus is a local concentration of repair-associated proteins, not a direct measurement of cancer prevention or younger tissue. The repair pattern also differed after other senescence-inducing insults. The findings therefore identify one context-dependent regulatory response, rather than a treatment that reverses all forms of senescence. Changes in transcription and protein abundance must be evaluated separately, as described in Vitamin D and Gene Expression. [2]

Established senescent fibroblasts: changing secretion

Sayegh and colleagues used primary skin fibroblasts that had been irradiated and then maintained for 14 days to establish a senescent state. They subsequently treated the cells with 10 nanomoles per litre calcitriol for 24 hours or seven days. Secretion of selected inflammatory mediators, including CCL2, interleukin-6 and interleukin-8, decreased, alongside a partial reduction in p38 signalling. The cytokine work included seven donors; repeated protein experiments are not additional donors. [3]

The senescence-associated secretory phenotype is the mixture of substances released by these cells. Changing that mixture could influence neighbouring cells and local immune responses. It does not show selective killing, resumed division or reversal of the original arrest. A limited washout observation in supplementary material is also insufficient to establish a general long-lasting effect. This distinction matters when connecting cell signalling with Vitamin D and Regeneration: renewal requires more than a reduction in one group of secreted molecules. [3]

The paper also reanalysed samples from an older-adult skin-challenge cohort, which is considered separately in the tissue-outcome review. It is not an independent new clinical trial. Despite the paper title using vitamin D3, the direct fibroblast intervention was calcitriol. Its human cohort used oral cholecalciferol. These forms must not be merged into one exposure. [3]

Contrary evidence in injured lung models

Guijarro and colleagues tested calcitriol in bleomycin-injured A549 cells, a lung-cancer-derived model, and in mouse lung injury. At five nanomoles per litre, calcitriol increased selected persistent damage and senescence-associated measures in the injured A549 cells. The added effect was not reproduced simply by calcitriol alone or by every injury condition, and lung myofibroblasts behaved differently. The study therefore supplies a material opposite direction, not proof of a universal pro-senescence action. [4]

The accompanying mouse findings included worse fibrosis and weight loss. These endpoints raise a tissue-level concern within that model, but are not a human trial of ordinary oral vitamin D3. The paper gives inconsistent bleomycin doses between sections, so an exact injury-dose comparison cannot be securely reconstructed here. Its statements about reactive oxygen species also do not support treating one oxidative route as an established mediator. The reliable point is cell: and insult-dependent worsening under the studied conditions. [4]

Malignant kidney cells: more senescence-associated features

Shen and colleagues exposed 786-O kidney-cancer cells to 100 nanomoles per litre calcitriol for 48 hours. They reported more JMJD3, an enzyme involved in removing methyl groups from histones, together with lower global H3K27me3, increased p16 and more senescence-associated beta-galactosidase staining. Reducing JMJD3 with small interfering RNA attenuated parts of the response. These experiments connect a proposed histone-related pathway to the observed cellular phenotype. The broader distinction between histone marks and gene activity is covered in Vitamin D and Epigenetic Regulation. [5]

However, the study did not establish stable irreversible arrest through a convincing withdrawal and recovery test. It did not isolate a particular gene-locus methylation change through epigenetic editing, and it did not directly perturb VDR to establish that step. Histone normalization and figure-label inconsistencies further limit fine interpretation. More senescence-associated features in a malignant cell can be investigated as a tumour-suppressive idea, but this paper does not establish clinical cancer treatment or an equivalent effect in healthy ageing tissue. [5]

DNA sensing: restoring a challenge response is a different endpoint

Cancado and colleagues examined late-passage, irradiated and progeria-related fibroblast models. Progeria is a rare premature-ageing disorder and does not reproduce every aspect of normal ageing. Seven days of 100 nanomoles per litre calcitriol improved selected responses to introduced DNA, including production of the messenger cGAMP and downstream STING signalling. These are components of a DNA-sensing defence pathway. The work tests responsiveness to a challenge, rather than merely asking whether an unstimulated inflammatory marker falls. [6]

A stronger response to introduced DNA is not evidence that senescent cells were cleared or that older people became more resistant to infection. The paper also contains a mouse lifespan experiment with H-151, a separate STING inhibitor. That lifespan extension must not be attributed to vitamin D. This study and the oncogene-repair paper come from the same broader research programme; their distinct experiments are complementary, not independent laboratory replications of one universal effect. [6] [2]

A skeletal pathway involving cell-cycle control

Xu and colleagues investigated active-hormone insufficiency in Cyp27b1-heterozygous mice and stress responses in cultured human marrow stromal cells. CYP27B1 helps generate active vitamin D. Their experiments connected VDR-dependent CDK2 transcription to P27 degradation, including promoter-binding and reporter tests, protein regulation and genetic P27 deletion. CDK2 and P27 participate in control of cell division. The data provide a more developed causal chain than a marker association alone. [7]

Nevertheless, deleting P27 is not vitamin D treatment and is not selective removal of senescent cells. Partial skeletal rescue in a global genetic model does not establish a safe anti-ageing intervention. The human cell experiments used oxidative stress and early-passage cultures, rather than proving reversal of ordinary long-term replicative ageing. The studies connect a regulatory pathway to selected cellular and skeletal phenotypes while leaving normal-human ageing and treatment efficacy unresolved. [7]

A small randomized human marker study

Rastgoo and colleagues randomized 88 older adults selected for vitamin D blood levels below 30 nanograms per millilitre into four groups for eight weeks. This was the study eligibility threshold, not a universal clinical definition of deficiency. The groups received 1,000 or 5,000 international units of vitamin D3 daily, with or without 600 milligrams of N-acetylcysteine. This was an active-dose comparison, not a placebo-controlled test of supplementation versus none; there was no N-acetylcysteine-only group. A formal correction establishes 5,000, rather than 50,000, international units in affected table labels. [8] [9]

The authors reported lower beta-galactosidase green area and selected p16 and inflammatory-gene measurements in the 5,000-unit groups compared with 1,000 units of vitamin D3 alone. These were measurements in peripheral blood mononuclear cells, a mixed group of immune cells. That comparison does not by itself show that adding N-acetylcysteine is better than 5,000 units alone. The beta-galactosidase assay measured green-stained pixel area, not a validated percentage of senescent immune cells. p21 expression did not significantly improve. Between-group differences in circulating interleukin-6, C-reactive protein and the neutrophil-to-lymphocyte ratio were not significant. An internal discrepancy in reported p16 numbers prevents a reliable precise fold-change claim. [8]

Randomization makes this a useful human contribution, but the small groups and short duration do not establish clearance of senescent cells, reversal of immune ageing or improved clinical resilience. Cell mixture and assay interpretation remain important. The null serum results must accompany the selected positive cellular signals, rather than being replaced by the broader claim that inflammation was reduced throughout the body. [8]

Comparing the actual scientific claims

ExperimentSupported findingClaim not established
Serial-passage stromal cellsSelected markers changed with slower proliferationExtended replicative lifespan or rejuvenated tissue
Oncogene-induced fibroblastsRepair-factor response improvedPrevention or reversal of the arrest
Established senescent skin fibroblastsSelected inflammatory secretions decreasedSelective clearance or renewed division
Lung-injury and kidney-cancer modelsSome senescence-associated features increasedA common effect in all healthy cells
DNA-challenge fibroblastsSelected DNA-sensing responses improvedClinical antiviral protection or vitamin D lifespan extension
Randomized older-adult trialSelected blood-cell measures differed by active regimenA proven fall in whole-body senescent-cell burden

The evidence supports modulation of particular senescence-related processes. It does not support using “anti-senescence” as a synonym for clearance, renewed division or slower ageing. Different triggers, cell states and endpoints explain why opposing results can be scientifically informative without cancelling each other or proving one universal mechanism. Translation to Vitamin D and Age-Related Decline requires actual tissue and human outcomes, rather than extending cellular language beyond what was measured.

Scientific sources

[1] 1,25-dihydroxyvitamin D3 treatment delays cellular aging in human mesenchymal stem cells while maintaining their multipotent capacity. Klotz B, Mentrup B, Regensburger M, Zeck S, Schneidereit J, Schupp N, Linden C, Merz C, Ebert R, Jakob F. PloS one. 2012;7(1):e29959. DOI 10.1371/journal.pone.0029959; PMID 22242193; PMCID PMC3252365.

[2] Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence. Graziano S, Johnston R, Deng O, Zhang J, Gonzalo S. Oncogene. 2016;35(41):5362-5376. DOI 10.1038/onc.2016.77; PMID 27041576; PMCID PMC5050051.

[3] Vitamin D3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing. Sayegh S, Fantecelle CH, Laphanuwat P, Subramanian P, Rustin MHA, Gomes DCO, Akbar AN, Chambers ES. Aging cell. 2024;23(4):e14093. DOI 10.1111/acel.14093; PMID 38287646; PMCID PMC11019144.

[4] Detrimental pro-senescence effects of vitamin D on lung fibrosis. Guijarro T, Magro-Lopez E, Manso J, Garcia-Martinez R, Fernandez-Aceñero MJ, Liste I, Zambrano A. Molecular medicine (Cambridge, Mass.). 2018;24(1):64. DOI 10.1186/s10020-018-0064-z; PMID 30567504; PMCID PMC6299997.

[5] Calcitriol induces cell senescence of kidney cancer through JMJD3 mediated histone demethylation. Shen Y, Yu D, Qi P, Wang X, Guo X, Zhang A. Oncotarget. 2017;8(59):100187-100195. DOI 10.18632/oncotarget.22124; PMID 29245970; PMCID PMC5725012.

[6] A noncanonical cGAS-STING pathway drives cellular and organismal aging. Cancado de Faria R, Silva LND, Teodoro-Castro B, McCommis KS, Shashkova EV, Gonzalo S. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(28):e2424666122. DOI 10.1073/pnas.2424666122; PMID 40638086; PMCID PMC12280946.

[7] Active vitamin D protects against osteoporosis by promoting VDR-dependent CDK2 transcription and P27 degradation. Xu F, Liu Q, Huang M, Wang J, Goltzman D, Gu B, Miao D. European journal of endocrinology. 2026;195(2):329-344. DOI 10.1093/ejendo/lvag152; PMID 42592858.

[8] Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in immunology. 2025;16:1570441. DOI 10.3389/fimmu.2025.1570441; PMID 40421021; PMCID PMC12104082.

[9] Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in Immunology. 2025;16:1627178. DOI 10.3389/fimmu.2025.1627178; PMID 40510343.

Related reading

Physiology

Vitamin D and Cellular Senescence

Explains the relationship between vitamin D and cellular senescence, including gene regulation, mitochondrial function, oxidative stress, and inflammatory signalling, and how these processes relate to ageing cells.

Read more →

Original sources

Source

1,25-Dihydroxyvitamin D3 Treatment Delays Cellular Aging in Human Mesenchymal Stem Cells while Maintaining Their Multipotent Capacity

We wanted to know if 1,25D3 is able to modulate aging processes on a cellular level in human mesenchymal stem cells (hMSC).

Publication details

[1] 1,25-dihydroxyvitamin D3 treatment delays cellular aging in human mesenchymal stem cells while maintaining their multipotent capacity. Klotz B, Mentrup B, Regensburger M, Zeck S, Schneidereit J, Schupp N, Linden C, Merz C, Ebert R, Jakob F. PloS one. 2012;7(1):e29959. DOI 10.1371/journal.pone.0029959; PMID 22242193; PMCID PMC3252365.

Read more →
Source

Vitamin D3 inhibits p38 MAPK and senescence‐associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing

Vitamin D3 replacement in older insufficient adults significantly improves their antigen‐specific varicella zoster virus (VZV) cutaneous immunity.

Publication details

[3] Vitamin D3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing. Sayegh S, Fantecelle CH, Laphanuwat P, Subramanian P, Rustin MHA, Gomes DCO, Akbar AN, Chambers ES. Aging cell. 2024;23(4):e14093. DOI 10.1111/acel.14093; PMID 38287646; PMCID PMC11019144.

Read more →
Source

Detrimental pro-senescence effects of vitamin D on lung fibrosis

The multiple biological effects of vitamin D and its novel activities on inflammation and redox homeostasis have raised high expectations on its use as a therapeutic agent for multiple fibrogenic conditions.

Publication details

[4] Detrimental pro-senescence effects of vitamin D on lung fibrosis. Guijarro T, Magro-Lopez E, Manso J, Garcia-Martinez R, Fernandez-Aceñero MJ, Liste I, Zambrano A. Molecular medicine (Cambridge, Mass.). 2018;24(1):64. DOI 10.1186/s10020-018-0064-z; PMID 30567504; PMCID PMC6299997.

Read more →
Source

A noncanonical cGAS-STING pathway drives cellular and organismal aging.

[6] A noncanonical cGAS-STING pathway drives cellular and organismal aging.

Publication details

[6] A noncanonical cGAS-STING pathway drives cellular and organismal aging. Cancado de Faria R, Silva LND, Teodoro-Castro B, McCommis KS, Shashkova EV, Gonzalo S. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(28):e2424666122. DOI 10.1073/pnas.2424666122; PMID 40638086; PMCID PMC12280946.

Read more →
Source

Active vitamin D protects against osteoporosis by promoting VDR-dependent CDK2 transcription and P27 degradation.

Published in Xu F, Liu Q, Huang M, Wang J, Goltzman D, Gu B, Miao D. European journal of endocrinology (2026).

Publication details

[7] Active vitamin D protects against osteoporosis by promoting VDR-dependent CDK2 transcription and P27 degradation. Xu F, Liu Q, Huang M, Wang J, Goltzman D, Gu B, Miao D. European journal of endocrinology. 2026;195(2):329-344. DOI 10.1093/ejendo/lvag152; PMID 42592858.

Read more →
Source

Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial.

Published in Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in immunology (2025).

Publication details

[8] Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in immunology. 2025;16:1570441. DOI 10.3389/fimmu.2025.1570441; PMID 40421021; PMCID PMC12104082.

Read more →
Source

Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial

Published in Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in Immunology (2025).

Publication details

[9] Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in Immunology. 2025;16:1627178. DOI 10.3389/fimmu.2025.1627178; PMID 40510343.

Read more →